Oestrogen receptor 1 mRNA is a prognostic factor in ovarian cancer patients treated with neo-adjuvant chemotherapy: Determination by array and kinetic PCR in fresh tissue biopsies

Endocrine-Related Cancer

Volumn 16, Issue 4, 2009, Pages 1241-1249

  Zamagni, Claudio ^a   Wirtz, Ralph M ^b   De Iaco, Pierandrea ^a   Rosati, Marta ^a   Veltrup, Elke ^b   Rosati, Federica ^a   Capizzi, Elisa ^c   Cacciari, Nicoletta ^a   Alboni, Carlo ^a   Bernardi, Alessandra ^a   Massari, Francesco ^a   Quercia, Sara ^a   Grigioni, Antonietta D'Errico ^c   Dietel, Manfred ^d   Sehouli, Jalid ^d   Denkert, Carsten ^d   Martoni, Andrea Angelo ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b SIEMENS AG   (Germany)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; MESSENGER RNA; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL ARTICLE; DRUG RESPONSE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MICROARRAY ANALYSIS; OVARY CANCER; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; TUMOR LOCALIZATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, PAPILLARY; CHEMOTHERAPY, ADJUVANT; CYSTADENOCARCINOMA, SEROUS; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; PACLITAXEL; PERITONEAL NEOPLASMS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 72549107611     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-08-0342     Document Type: Article

References (28)

1. Ahlgren JD, Ellison NM, Gottlieb RJ, Laluna F, Lokich JJ, Sinclair PR, Ueno W, Wampler GL, Yeung KY, Alt D et al. 1993 Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program. Journal of Clinical Oncology 11 1957-1968. (Pubitemid 23304622)
2. Bowman A, Gabra H, Langdon SP, Lessells A, Stewart M, Young A & Smyth JF 2002 CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup. Clinical Cancer Research 8 2233-2239. (Pubitemid 34753595)
3. Bristow RE & Chi DS 2006 Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecologic Oncology 103 1070-1076. (Pubitemid 44821335)
4. Buzdar A, Jonat W, Howell A, Jones SE, Blomqvist CP, Vogel CL, Eiermann W, Wolter JM, Steinberg M, Webster A et al. 1998 Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer 83 1142-1152. (Pubitemid 28419067)
5. Buzdar A, Douma J, Davidson N, Elledge R, Morgan M, Smith R, Porter L, Nabholtz J, Xiang X & Brady C 2001 Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. Journal of Clinical Oncology 19 3357-3366. (Pubitemid 32642188)
6. del Carmen MG, Fuller AF, Matulonis U, Horick NK, Goodman A, Duska LR, Penson R, Campos S, Roche M & Seiden MV 2003 Phase II trial of anastrozole in women with asymptomatic mullerian cancer. Gynecologic Oncology 91 596-602. (Pubitemid 38388157)
7. Darb-Esfahani S, Wirtz RM, Sinn BV, Budczies J, Noske A, Weichert W, Fagged A, Scharff S, Sehouli J, Oskay-Özcelik G et al. 2009 Estrogen receptor 1 mRNA is a prognostic factor in ovarian carcinoma: determination by kinetic PCR in formalin-fixed paraffin-embedded tissue. Endocrine-Related Cancer 16 1229-1239.
8. Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J, Bezwoda W, Gardin G, Gudgeon A, Morgan M et al. 1998 Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. Journal of Clinical Oncology 16 453-461.
9. Early Breast Cancer Trialists' Collaborative Group 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 1687-1717. (Pubitemid 40719106)
10. Ferlay J, Bray F, Pisani P & Markin DM 2004 GLOBOCAN 2002 Cancer Incidence, Mortality and Prevalence Worldwide. IARC Cancer Base No.5 Version 2.0. Lyon, France: IARC Press. Database on the internet available from http://www-dep.iarc.fr/.
11. Hatch KD, Beecham JD, Blessing JA & Creasman WT 1991 Responsiveness of patients with advanced ovarian carcinoma to tamoxifen: a Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer 68 269-271.
12. Howell A, Robertson JF, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg UR, Vergote I, Erikstein B, Webster A & Morris C 2002 Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. Journal of Clinical Oncology 20 3396-3403. (Pubitemid 34894672)
13. Ihnen M, Müller V, Wirtz RM, Schroder C, Krenkel S, Witzel I, Lisboa BW, Janicke F & Milde-Langosch K 2008 Predictive impact of activated leukocyte cell adhesion molecule (ALCAM/CD166) in breast cancer. Breast Cancer Research and Treatment 112 419-427.
14. Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Cervek J, Fowst C, Polli A, Di Salle E, Massimini G et al. 2000 Exemestane improves survival compared with megoestrol acetate in postmenopausal patients with advanced breast cancer who have failed on tamoxifen. Results of a double-blind randomised phase III trial. European Journal of Cancer 36 S86-S87. (Pubitemid 30803670)
15. Langdon SP, Hawkes MM, Lawrie SS, Hawkins RA, Tesdale AL, Crew AJ, Miller WR & Smyth JF 1990 Estrogen receptor expression and the effect of tamoxifen on the growth of human ovarian carcinoma cell lines. British Journal of Cancer 62 213-216. (Pubitemid 20242438)
16. Langdon SP, Crew AJ, Ritchie AA, Muir M, Wakeling A, Smyth JF & Miller WR 1994 Growth inhibition of oestrogen receptor-positive human ovarian carcinoma by anti-oestrogens in vitro and in a xenograft model. European Journal of Cancer 30A 682-686. (Pubitemid 24164260)
17. Le T, Williams K, Sentermann M, Hopkins L, FaughtW& Fung-Kee-Fung M 2007 Histopathologic assessment of chemotherapy effects in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking. Gynecologic Oncology 106 160-163. (Pubitemid 46898585)
18. Markman M, Iseminger KA, Hatch KD, Creasman WT, Barnes W & Dubeshter B 1996 Tamoxifen in platinumrefractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report. Gynecologic Oncology 62 4-6. (Pubitemid 26234538)
19. Mazzeo F, Berliere M, Kerger J, Squifflet J, Duck L, D'Hondt V, Humblet Y, Donnez J & Machiels JP 2003 Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer. Gynecologic Oncology 90 163-169. (Pubitemid 37338092)
20. O'Donnell AJ, Macleod KG, Burns DJ, Smyth JF & Langdon SP 2005 Estrogen receptor-alpha mediates gene expression changes and growth response in ovarian cancer cells exposed to estrogen. Endocrine-Related Cancer 12 851-866.
21. Ogston KN, Miller ID, Payne S, Hutcheon AW, Sarkar TK, Smith I, Schofield A & Heys SD 2003 A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast 12 320-327. (Pubitemid 37322062)
22. Papadimitriou CA, Markaki S, Siapkaras J, Vlachos G, Efstathiou E, Grimani I, Hamilos G, Zorzou M & Dimopoulos MA 2004 Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long term results of a phase II study. Oncology 66 112-117.
23. Rao GG & Miller DS 2006 Hormonal therapy in epithelial ovarian cancer. Expert Review of Anticancer Therapy 6 43-47.
24. Sassen S, Schmalfeldt B, Avril N, Kuhn W, Busch R, Hofler H, Fend F & Nahrig J 2007 Histopathologic assessment of tumor regression after neoadjuvant chemotherapy in advanced-stage ovarian cancer. Human Pathology 38 926-934. (Pubitemid 46726516)
25. Schwartz PE, Rutherford TJ, Chambers JT, Kohorn EI & Thiel RP 1999 Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. Gynecologic Oncology 72 93-99. (Pubitemid 29045454)
26. Tropè C, Marth C & Kaern J 2000 Tamoxifen in the treatment of recurrent ovarian carcinoma. European Journal of Cancer 36 S59-S61. (Pubitemid 30803658)
27. Vergote IB 2008 EORTC 55971: a randomized phase III study comparing upfront debulking surgery vs neoadjuvant chemotherapy in patients with stage IIIC or IV epithelial ovarian carcinoma. 12th Biennal Meeting International Gynecologic Cancer Society, Bangkok, October 25-28, 2008 (late breaking abstract).
28. Vergote IB, De Wever I, Decloedt J, Tjalma W, Van Gramberen M & van Dam P 2000 Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer. Seminars in Oncology 27 31-36. (Pubitemid 30643850)